Quarterly report pursuant to Section 13 or 15(d)

Royalty Purchase Agreements - Aronora (Details)

v3.21.1
Royalty Purchase Agreements - Aronora (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Apr. 07, 2019
USD ($)
item
Sep. 30, 2019
USD ($)
Mar. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Agreements        
Long-term royalty receivables     $ 48,075 $ 34,575
Contingent consideration under royalty purchase agreements     75 75
Impairment of long-term royalty receivable     0 $ 0
Payments to acquire milestones and royalties     13,500  
Aronora | Royalty Purchase Agreement        
Agreements        
Number of drug candidates | item 5      
Non-royalties to be received (as a percent) 10.00%      
Future non-royalty payments to be received (as a percent) 5.00%      
Multiplier for cumulative amount of consideration paid | item 2      
Upfront payment $ 6,000      
Threshold amount of cumulative royalties on net sales per product 250,000      
Long-term royalty receivables 9,000      
Contingent consideration under royalty purchase agreements 3,000   0  
Payments of contingent consideration   $ 3,000    
Impairment of long-term royalty receivable     $ 0  
Aggregate milestones payments per product 85,000      
Aronora | Royalty Purchase Agreement | Silicon Valley Bank Loans        
Agreements        
Upfront payment $ 3,000      
Aronora | Royalty Purchase Agreement | Bayer Products        
Agreements        
Number of drug candidates | item 3      
Number of drug candidates subject to exclusive license option | item 1      
Royalties on net sales (as a percent) 100.00%      
Non-royalties to be received (as a percent) 10.00%      
Contingent future cash payment for each product $ 1,000      
Potential future cash payments $ 3,000      
Aronora | Royalty Purchase Agreement | Non-Bayer Products        
Agreements        
Number of drug candidates | item 2      
Non-royalties to be received (as a percent) 10.00%